Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Neluxicapone with Levodopa/Carbidopa in Healthy Males
NCT03055936Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Feb 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of neluxicapone in Parkinson's disease (PD) (16 arms), sponsored by Orion Corporation. Primary endpoint: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample. Started Feb 2017; status: completed.
02
Drugs
neluxicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03055936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055936.